Loading...
Loading...
Citi Investment Research has a Buy rating and a $29 price target on shares of Warner Chilcott Plc
WCRX.
In a note to clients, Citi writes, "We Hosted a Dinner with CFO, Paul Herendeen. We recommend buying WCRX's shares, which trade at a trough multiple of 5.4x our ‘12 EPS of $4.14, reflecting -56%/-65% discounts to the S&P 500/specialty pharma peers. Our $29 PT is supported by a $35 DCF value. We believe the Street is overly concerned with the Actonel/Atelvia franchise, while not factoring in its success with its more profitable franchises."
Shares of WCRX lost 72 cents yesterday to close at $22.24, a loss of 3.1%.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst ColorPrice TargetAnalyst RatingsCiti Investment ResearchHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in